Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500955PMID: 30000014
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1610943-06-0
Drug Levels and Effects
Summary of Use during Lactation
A low level of emicizumab was found in the milk of one woman. The drug is likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[1] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[2]
Drug Levels
Maternal Levels. A woman with severe hemophilia A received emicizumab every 4 weeks (dose not stated, but probably 6 mg/kg) throughout pregnancy and postpartum as well as recombinant factor VIIa (NovoSeven) 90 mcg/kg every 2 hours initially with a gradually increasing dosage interval postpartum for severe bleeding. A milk sample taken at an unreported time contained 38 mg/L of emicizumab.[3]
Infant Levels. A woman with severe hemophilia A was receiving emicizumab every 4 weeks (dose not stated, but probably 6 mg/kg) throughout pregnancy and postpartum as well as recombinant factor VIIa (NovoSeven) 90 mcg/kg every 2 hours initially with a gradually increasing dosage interval postpartum for severe bleeding. A serum sample taken from the infant at an unreported time contained 106 mg/L of emicizumab, probably obtained transplacentally.[3]
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]
- 2.
- Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023;22:350-66. [PubMed: 36931808]
- 3.
- Kharel Z, Pruthi RK, Kouides PA, Reid R. Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor. Blood 2023;142:5492. doi:10.1182/blood-2023-190012 [CrossRef]
Substance Identification
Substance Name
Emicizumab
CAS Registry Number
1610943-06-0
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Risankizumab.[Drugs and Lactation Database (...]Review Risankizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Benralizumab.[Drugs and Lactation Database (...]Review Benralizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Ravulizumab.[Drugs and Lactation Database (...]Review Ravulizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Ixekizumab.[Drugs and Lactation Database (...]Review Ixekizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Sutimlimab.[Drugs and Lactation Database (...]Review Sutimlimab.. Drugs and Lactation Database (LactMed®). 2006
- Emicizumab - Drugs and Lactation Database (LactMed®)Emicizumab - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...